Loading
A Singapore microRNA diagnostics company with a stomach cancer blood test and a multi-cancer test in development.
Mirxes sells GASTROClear, a microRNA blood test for gastric cancer that it reports holds FDA Breakthrough Device designation (August 2023) and NMPA approval (October 2025). Its multi-cancer screening test is in development through Project CADENCE (NCT05633342), launched in July 2022 for up to nine cancers using microRNA and DNA methylation; no multi-cancer results were found.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA), Gastric & gastro-oesophageal junction cancer.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/